Comprehensive Spectral Flow Cytometry Approach for Concurrent Analysis of Hematopoietic Stem, Progenitor, and Mature Cell Lineages in Murine Bone Marrow - Takeaways - MDSpire

Comprehensive Spectral Flow Cytometry Approach for Concurrent Analysis of Hematopoietic Stem, Progenitor, and Mature Cell Lineages in Murine Bone Marrow

  • By

  • Léa Girondier

  • Manon Richaud

  • Julien MP Grenier

  • Ana Belen Pérez-Oliva

  • Jenny Van Asbeck-van der Wijst

  • Michel Aurrand-Lions

  • Maria De Grandis

  • Christophe Lachaud

  • Cyril Fauriat

  • Laura Braud

  • March 18, 2026

  • 0 min

Share

  • 1

    A 19-marker spectral flow cytometry panel was developed to analyze hematopoietic stem, progenitor, and mature cell lineages in murine bone marrow.

  • 2

    This integrated approach allows simultaneous identification of various hematopoietic populations from a single sample, enhancing research efficiency.

  • 3

    Validation confirmed accurate detection of long-term and short-term HSCs, multipotent progenitors, and all erythroid maturation stages.

  • 4

    The panel effectively detected hematopoietic alterations in aged and β-thalassemic mouse models, demonstrating its applicability in pathological conditions.

  • 5

    This tool supports the evaluation of emerging therapies by allowing precise monitoring of hematopoietic progenitor targeting and treatment effects.

Original Source(s)

Comprehensive Spectral Flow Cytometry Approach for Concurrent Analysis of Hematopoietic Stem, Progenitor, and Mature Cell Lineages in Murine Bone Marrow

  • by Léa Girondier, Manon Richaud, Julien MP Grenier, Ana Belen Pérez-Oliva, Jenny Van Asbeck-van der Wijst, Michel Aurrand-Lions, Maria De Grandis, Christophe Lachaud, Cyril Fauriat, Laura Braud

  • March 18, 2026

Related Content

Molecular Identification of HTLV-1 and HCV Infections in Sickle Cell Disease Patients Undergoing Multiple Transfusions in Kinshasa: A Case Study of CMMASS

A Family at War—Against Tropheryma whipplei: A Case Series

Momelotinib in JAK2 inhibitor-naïve myelofibrosis: pros and cons